

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re: Daun et al.  
Application Serial No.: 10/753,261  
Filed: January 7, 2004  
For: NOVEL DEAZAPURINES AND USES THEREOF

Confirmation No.: 6698  
Group Art Unit: 1625  
Examiner: Owens

Date: March 26, 2007

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**INFORMATION DISCLOSURE STATEMENT  
PURSUANT TO 37 C.F.R. §1.97(c)**

Sir:


Attached is a list of documents, together with a copy of any listed foreign patent document and/or non-patent literature. A copy of any listed U.S. patent and/or U.S. patent application publication is not provided herewith in accordance with the amendment by the U.S. Patent and Trademark Office to 37 C.F.R. § 1.98(a)(2)(ii) effective October 21, 2004.

This Information Disclosure Statement is submitted in accordance with 37 C.F.R. § 1.97(c), before final Office Action or Allowance, whichever is earlier.

In accordance with the requirements of 37 C.F.R. § 1.97(c)(2), the Commissioner is authorized to charge the \$180.00 fee specified in 37 C.F.R. § 1.17(p) to Deposit Account 50-0220. This amount is believed to be correct. However, the Commissioner is authorized to charge any deficiency or credit any overpayment to Deposit Account No. 50-0220.

It is requested that these documents be considered by the Examiner and officially made of record in accordance with the provisions of 37 C.F.R. § 1.56 and Section 609 of the MPEP.

Respectfully submitted,

  
Kenneth D. Sibley  
Registration No. 31,665

**USPTO Customer No. 20792**  
Myers Bigel Sibley & Sajovec, P.A.  
P. O. Box 37428, Raleigh, NC 27627  
Telephone: (919) 854-1400  
Facsimile: (919) 854-1401

**CERTIFICATION OF TRANSMISSION**

I hereby certify that this correspondence is being transmitted via the Office electronic filing system in accordance with § 1.6(a)(4) to the U.S. Patent and Trademark Office on March 26, 2007.

Signature: Sarah Abraham  
Typed Name of Person Signing Certificate: Sarah Abraham  
572818

Date: March 26, 2007

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 1

## Complete if Known

Application Number	10/753,261
Filing Date	January 7, 2004
First Named Inventor	Daun
Group Art Unit	1625
Examiner Name	Amelia Owens
Attorney Docket Number	9626.9IPX

## U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code (if known)			
		US- 4,877,810	10-31-1989	Mickle et al.	
		US- 4,939,146	07-02-1990	Kramer et al.	
		US- 4,999,365	03-12-1991	Dage et al.	
		US- 5,002,965	03-26-1991	Ramwell et al.	
		US- 5,618,785	04-08-1997	Heavner et al.	
		US- 5,632,991	05-27-1997	Gimbrone, Jr.	
		US- 5,728,685	03-17-1998	Abbas et al.	
		US- 6,048,841	04-11-2000	Baxter et al.	
		US- 6,110,967	08-29-2000	Asao et al.	claims 21-23
		US- 6,358,978 B1	03-19-2002	Ritzeler et al.	
		US- 6,608,072 B1	08-19-2003	Révész	
		US- 6,693,108 B2	02-17-2004	Green et al.	claim 11
		US- 6,747,053 B2	06-08-2004	Gabriel et al.	claim 36
		US- 6,884,804 B2	04-26-2005	Choon-Moon	claim 24
		US- 7,186,683 B2	03-06-2004	Henriksen et al.	claim 3

## FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
		Country Code Number Kind Code (if known)				
		EP 1 224 185 B1	11-30-2005	Novartis AG		
		EP 1 194 425 B1	01-04-2001	Aventis Pharma Deutschland GmbH		
		AU 2001112728 B2	08-05-2001	Aventis Pharma Deutschland GmbH		

## NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	
		International Search Report for corresponding International Application PCT/US/2004/00293 (WO 2004/063336 A3) (07-29-2004)	
		HAKOMORI, S, Tumor Malignancy Defined by Aberrant Glycosylation and Sphingo(glycol)lipid Metabolism, Cancer Research (December 1, 1996) pp 5309-5318, vol 56	
		DIMITROFF, C J, et al., Identification of Leukocyte E-Selectin Ligands, P-Selectin Glycoprotein Ligand-1 and E-Selectin Ligand-1, on Human Metastatic Prostate Tumor Cells, Cancer Res 2005 (July 1, 2005) pp 5750-5760, vol 65:13, www.aacrjournals.org	

iDoc# 572822

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.